Healthcare

By

Timothy Collins

 | Feb 5, 2015 | 1:25 PM EST

Coming up with a thesis from the five-minute chart.

By

TheStreet

 | Feb 4, 2015 | 1:45 PM EST

The debate raging among investors about hepatitis C revenue declines.

By

Bret Jensen

 | Jan 29, 2015 | 9:46 AM EST

I am adding allocation to healthcare.

By

Gary Berman

 | Jan 20, 2015 | 10:01 AM EST

I would look to buy the weakness inside the $102.30-$100.59 zone.

By

Timothy Collins

 | Jan 13, 2015 | 12:43 PM EST

Yesterday's action in the stock speaks volumes.

By

Kate Stalter

 | Jan 6, 2015 | 12:00 PM EST

They are prone to being whipsawed by news.

By

Chris Laudani

 | Dec 30, 2014 | 11:00 AM EST

Its hepatitis C drug will dominate the market.

By

Carolyn Boroden

 | Dec 29, 2014 | 9:00 AM EST

Here's how to trade some key price relationships.

By

David Katz

 | Dec 26, 2014 | 12:30 PM EST

Its hepatitis C drug is better; the stock trades at a discount.

By

Bret Jensen

 | Dec 26, 2014 | 11:18 AM EST

A high risk/high reward play.

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.